Tafalgie Therapeutics at BIO 2025! We are pleased to announce our presence at BIO Convention 2025, the must-attend event for the biotech industry, under the pavilion of the European Innovation Council (EIC). As the world’s largest event in biotech, the BIO International Convention 2025 is expected to attract over 20,000 professionals from across the biotech […]
Lire la suiteTafalgie Therapeutics appoints Tanja Ouimet to its Supervisory Board Tafalgie Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of non-opioid pain-relieving peptides with a novel mechanism of action, announces the appointment of Tanja Ouimet,PhD, as a member of the Supervisory Board. This appointment, effective September 26, 2024, marks a strategic milestone for the company. […]
Lire la suiteDepartmental prize for research in Provence 2024 Aziz Moqrich, CNRS Research Director, Vice-President and Scientific Director of Tafalgie Therapeutics, receives the Departmental Prize for Research in Provence 2024, in the Grand Prix category. This award recognizes Dr Aziz Moqrich’s contribution to the advancement of research in the field of neuroscience. In particular, his research has […]
Lire la suiteTafalgie Therapeutics is one of Le Point magazine’s 2024 favorites. A big thank you for this wonderful spotlight on our work and our dedication to revolutionizing pain treatment! We are proud to be among Magazine Le Point’s 2024 top picks and to contribute, alongside other champions of French excellence, to advancing health research. This recognition […]
Lire la suiteMarseille-based biotech launches a new generation of painkillers Marseille-based biotech has just been selected by the European Innovation Council for its molecules as alternatives to opioids.
Lire la suiteTafalgie Therapeutics: an alternative painkiller to opioids Tafalgie Therapeutics is developing a new generation of pain-relieving peptides devoid of the disabling side effects of opioids. This start-up is one of Challenges’ “100 start-ups to invest in in 2024”.
Lire la suiteTafalgie Therapeutics to benefit from the EIC Accelerator Program We are proud to announce that Tafalgie Therapeutics is one of only 47[JS1] European companies (12 of which are French) to have been selected in the November 2023 call for proposals for the European Innovation Council (EIC) “Accelerator” program, which rewards companies displaying excellence in the […]
Lire la suiteTafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specializing in the development of treatments for relieving and preventing acute and chronic pain (inflammatory, postoperative, neuropathic) without adverse effects, is pleased to announce that its teams are today moving to a new site with dedicated research and support […]
Lire la suiteTafalgie Therapeutics will participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year Tafalgie Therapeutics, a biopharmaceutical research company specializing in research and innovation for treatments to alleviate and prevent acute and chronic pain (inflammatory, postoperative, neuropathic) without side effects is proud to announce that it has been […]
Lire la suiteAziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 protein Dr Moqrich is Research Director at the IBDM laboratory (part of the CNRS, the French National Center for Scientific Research) and cofounder of Tafalgie Therapeutics. Th award recognizes the major discoveries he and his team have made, […]
Lire la suite